Since MDSC levels in the peripheral blood of patients with head and neck cancer, non-small-cell lung cancer, breast cancer are positively correlated with plasma level of VEGF-A, VEGF-targeted therapy could induce a decrease of MDSCs in peripheral blood of cancer patients (27). The gene discussed is VEGFA; the disease is head and neck cancer.